Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may end guesswork in psoriasis dosing

NCT ID NCT06398106

Disease control Sponsor: University Hospital, Ghent Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether measuring biologic drug levels in the blood can help doctors adjust doses for people with psoriasis. About 210 adults on certain biologics will either get dose advice based on blood tests or continue standard care. The goal is to maintain disease control while reducing side effects and costs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 210 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults; aged 18 years or older 2. Documented diagnosis of psoriasis (predominantly type vulgaris; based on clinical diagnosis) by an accredited dermatologist 3. Patients must be currently treated with secukinumab, ixekizumab or guselkumab ≥ 6 months according to the standard dosing scheme. 4. The subject signs and dates a written informed consent form and any required privacy authorization prior to the initiation of any study procedures Exclusion Criteria: 1. Another indication than plaque psoriasis as the main indication for biologic use (e.g. receives biologic for rheumatoid arthritis as the main indication) 2. Concomitant use of systemic immunosuppressants other than methotrexate or acitretin (e.g. prednisone, cyclosporine etc) 3. Severe comorbidities with short life-expectancy (e.g. metastasized tumour) or uncontrolled PsA at inclusion/baseline 4. Presumed inability to follow the study protocol 5. Active pregnancy wish

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis vulgaris are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis vulgaris

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AZ Alma

    RECRUITING

    Eeklo, 9900, Belgium

  • AZ Maria Middelares

    RECRUITING

    Ghent, Belgium

  • AZ Sint-Jan

    RECRUITING

    Bruges, Belgium

  • CHU Liège

    ACTIVE_NOT_RECRUITING

    Liège, Belgium

  • CHU Saint-Pierre

    RECRUITING

    Brussels, 1000, Belgium

  • Clinique André Renard

    WITHDRAWN

    Herstal, Belgium

  • Dermatologie Handelskaai

    RECRUITING

    Kortrijk, Belgium

  • Dermatologie Maldegem

    RECRUITING

    Maldegem, Belgium

  • Dermatologiepraktijk huidziekten Geel

    RECRUITING

    Geel, Belgium

  • Grand Hôpital de Charleroi

    ACTIVE_NOT_RECRUITING

    Charleroi, Belgium

  • UCL Saint-Luc

    ACTIVE_NOT_RECRUITING

    Brussels, Belgium

  • ULB Erasme

    NOT_YET_RECRUITING

    Brussels, Belgium

  • UZ Brussel

    RECRUITING

    Brussels, Belgium

  • UZ Gent

    RECRUITING

    Ghent, Belgium

  • UZ Leuven

    RECRUITING

    Leuven, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.